Mayne Pharma Group Limited (MYX.AX)
- Previous Close
6.75 - Open
6.70 - Bid 6.57 x 78655600
- Ask 6.74 x 42535300
- Day's Range
6.51 - 6.75 - 52 Week Range
2.75 - 7.40 - Volume
130,562 - Avg. Volume
211,216 - Market Cap (intraday)
566.595M - Beta (5Y Monthly) 1.32
- PE Ratio (TTM)
-- - EPS (TTM)
-3.18 - Earnings Date Feb 26, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 18, 2023
- 1y Target Est
7.04
Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. The company operates through four segments: International Branded Products, and Portfolio Product Division. It provides oral drug delivery systems; and contract development and manufacturing services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.
www.maynepharma.com--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Industry
Recent News: MYX.AX
Performance Overview: MYX.AX
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYX.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYX.AX
Valuation Measures
Market Cap
566.59M
Enterprise Value
448.36M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.03
Price/Book (mrq)
1.03
Enterprise Value/Revenue
1.67
Enterprise Value/EBITDA
-5.40
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.21%
Return on Assets (ttm)
-5.46%
Return on Equity (ttm)
-40.74%
Revenue (ttm)
319.28M
Net Income Avi to Common (ttm)
-274.18M
Diluted EPS (ttm)
-3.18
Balance Sheet and Cash Flow
Total Cash (mrq)
154.81M
Total Debt/Equity (mrq)
6.68%
Levered Free Cash Flow (ttm)
46.43M